Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease : Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial
| dc.contributor.author | Wilcock, Gordon K | |
| dc.contributor.author | Gauthier, Serge | |
| dc.contributor.author | Frisoni, Giovanni B | |
| dc.contributor.author | Jia, Jianping | |
| dc.contributor.author | Hardlund, Jiri H | |
| dc.contributor.author | Moebius, Hans J | |
| dc.contributor.author | Bentham, Peter | |
| dc.contributor.author | Kook, Karin A | |
| dc.contributor.author | Schelter, Bjoern Olaf | |
| dc.contributor.author | Wischik, Damon J | |
| dc.contributor.author | Davis, Charles S | |
| dc.contributor.author | Staff, Roger T | |
| dc.contributor.author | Vuksanovic, Vesna | |
| dc.contributor.author | Ahearn, Trevor | |
| dc.contributor.author | Bracoud, Luc | |
| dc.contributor.author | Shamsi, Kohkan | |
| dc.contributor.author | Marek, Ken | |
| dc.contributor.author | Seibyl, John | |
| dc.contributor.author | Riedel, Gernot | |
| dc.contributor.author | Storey, John M. D. | |
| dc.contributor.author | Harrington, Charles R | |
| dc.contributor.author | Wischik, Claude M | |
| dc.contributor.institution | University of Aberdeen.Physics | en |
| dc.contributor.institution | University of Aberdeen.Institute for Complex Systems and Mathematical Biology (ICSMB) | en |
| dc.contributor.institution | University of Aberdeen.Medical Sciences | en |
| dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
| dc.contributor.institution | University of Aberdeen.Aberdeen Biomedical Imaging Centre | en |
| dc.contributor.institution | University of Aberdeen.Chemistry | en |
| dc.date.accessioned | 2017-12-06T17:43:23Z | |
| dc.date.available | 2017-12-06T17:43:23Z | |
| dc.date.issued | 2017-11-28 | |
| dc.description | The supplementary material is available in the electronic version of this article: http://dx.doi.org/10.3233/JAD-170560. The study was sponsored by TauRx Therapeutics (Singapore). We thank Lon Schneider and Howard Feldman for their contribution to the Scientific Advisory Board. We gratefully acknowledge study investigators and the generosity of study participants. Authors’ disclosures available online (http://j-alz.com/manuscript disclosures/17-0560r3). | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 24 | |
| dc.format.extent | 1832124 | |
| dc.identifier | 108289857 | |
| dc.identifier | 6ed5919c-278e-4174-ac1f-456eb22145a6 | |
| dc.identifier | 85036556784 | |
| dc.identifier.citation | Wilcock, G K, Gauthier, S, Frisoni, G B, Jia, J, Hardlund, J H, Moebius, H J, Bentham, P, Kook, K A, Schelter, B O, Wischik, D J, Davis, C S, Staff, R T, Vuksanovic, V, Ahearn, T, Bracoud, L, Shamsi, K, Marek, K, Seibyl, J, Riedel, G, Storey, J M D, Harrington, C R & Wischik, C M 2017, 'Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease : Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial', Journal of Alzheimer's Disease, vol. 61, no. 1, pp. 435-457. https://doi.org/10.3233/JAD-170560 | en |
| dc.identifier.doi | 10.3233/JAD-170560 | |
| dc.identifier.iss | 1 | en |
| dc.identifier.issn | 1387-2877 | |
| dc.identifier.other | ORCID: /0000-0002-5261-5467/work/73579133 | |
| dc.identifier.other | ORCID: /0000-0003-2250-3920/work/47672895 | |
| dc.identifier.uri | http://hdl.handle.net/2164/9693 | |
| dc.identifier.url | https://www.j-alz.com/vol61-1 | en |
| dc.identifier.vol | 61 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Journal of Alzheimer's Disease | en |
| dc.subject | ADAS-cog | en |
| dc.subject | Alzheimer’s disease | en |
| dc.subject | amyloid protein | en |
| dc.subject | clinical trial | en |
| dc.subject | cohort study | en |
| dc.subject | methylthioninium | en |
| dc.subject | tau protein | en |
| dc.subject | treatment | en |
| dc.subject | RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry | en |
| dc.subject.lcc | RC0321 | en |
| dc.title | Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease : Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial | en |
| dc.type | Journal article | en |
